Az afrikai sertéspestis jârvânytana és a védekezés lehetôségei

F. Olasz, Istvàn Mésziros, Vivien Tamàs, Âdim Bélint, Matgorzata Bruczynska, Grzegorz Wozniakowski, Zoltin Zédori

Research output: Article

Abstract

The first African swine fever (ASF) cases outside Africa were diagnosed in Portugal in 1957. Since 2017 the African swine fever virus (ASFV) has been continuously spreading in Eastern Europe, then it arrived to Asia, and by now it became the biggest economic and animal health threat to the swine industry of the world. In Europe both the wild boar and domestic pig populations are affected by the disease. ASFV is very resistant against environmental and physical effects and it may remain infectious in carcasses for months. This resistance largely contributes to the fact that ASFV infection can be sustained for a prolonged time even in low density wild boar populations. Depending on the infectious route, the virulence of the strain and the quantity of the acting virus, the course and symptoms of the disease can vary significantly. Peracute, acute, subacute and chronic forms of the disease can be distinguished. So far a few genes were shown to have an impact on the virulence of the virus, including the members of two multigene families (MGF 360 and MGF 505), and the genes DP71L, DP96R and DB69R (UK). Vaccine developments based on classical attenuation and virus inactivation methods failed to produce safe and effective vaccines against ASFV. Based on the available data, it seems that the development of live attenuated vaccines by targeted mutagenesis can bring a breakthrough in vaccine development, however, there are still a lot of problems to be solved. Vaccine research is hampered by the lack of established continuous cell lines in which ASFV can be propagated in high titer without genetic changes. A great variety of immunological and DNA based tests can be applied to diagnose ASFV, however, the use of PCR and immunoperoxidase staining are the most reliable methods used in practice. Since currently there is no available vaccine, the most effective defensive measures against the virus are the implementation of rigorous biosafety and biosecurity standards on the pig farms to prevent viral infection of the livestock.

Original languageHungarian
Pages (from-to)101-115
Number of pages15
JournalMagyar Allatorvosok Lapja
Volume141
Issue number2
Publication statusPublished - febr. 1 2019

Fingerprint

African Swine Fever Virus
African swine fever virus
Vaccines
Sus scrofa
viruses
wild boars
vaccine development
live vaccines
Virus Diseases
vaccines
Viruses
Virulence
African Swine Fever
virulence
Swine
pork industry
African swine fever
Virus Inactivation
Eastern Europe
Attenuated Vaccines

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Olasz, F., Mésziros, I., Tamàs, V., Bélint, Â., Bruczynska, M., Wozniakowski, G., & Zédori, Z. (2019). Az afrikai sertéspestis jârvânytana és a védekezés lehetôségei. Magyar Allatorvosok Lapja, 141(2), 101-115.

Az afrikai sertéspestis jârvânytana és a védekezés lehetôségei. / Olasz, F.; Mésziros, Istvàn; Tamàs, Vivien; Bélint, Âdim; Bruczynska, Matgorzata; Wozniakowski, Grzegorz; Zédori, Zoltin.

In: Magyar Allatorvosok Lapja, Vol. 141, No. 2, 01.02.2019, p. 101-115.

Research output: Article

Olasz, F, Mésziros, I, Tamàs, V, Bélint, Â, Bruczynska, M, Wozniakowski, G & Zédori, Z 2019, 'Az afrikai sertéspestis jârvânytana és a védekezés lehetôségei', Magyar Allatorvosok Lapja, vol. 141, no. 2, pp. 101-115.
Olasz F, Mésziros I, Tamàs V, Bélint Â, Bruczynska M, Wozniakowski G et al. Az afrikai sertéspestis jârvânytana és a védekezés lehetôségei. Magyar Allatorvosok Lapja. 2019 febr. 1;141(2):101-115.
Olasz, F. ; Mésziros, Istvàn ; Tamàs, Vivien ; Bélint, Âdim ; Bruczynska, Matgorzata ; Wozniakowski, Grzegorz ; Zédori, Zoltin. / Az afrikai sertéspestis jârvânytana és a védekezés lehetôségei. In: Magyar Allatorvosok Lapja. 2019 ; Vol. 141, No. 2. pp. 101-115.
@article{ecd638bc042c493686c655f4bb07654f,
title = "Az afrikai sert{\'e}spestis j{\^a}rv{\^a}nytana {\'e}s a v{\'e}dekez{\'e}s lehet{\^o}s{\'e}gei",
abstract = "The first African swine fever (ASF) cases outside Africa were diagnosed in Portugal in 1957. Since 2017 the African swine fever virus (ASFV) has been continuously spreading in Eastern Europe, then it arrived to Asia, and by now it became the biggest economic and animal health threat to the swine industry of the world. In Europe both the wild boar and domestic pig populations are affected by the disease. ASFV is very resistant against environmental and physical effects and it may remain infectious in carcasses for months. This resistance largely contributes to the fact that ASFV infection can be sustained for a prolonged time even in low density wild boar populations. Depending on the infectious route, the virulence of the strain and the quantity of the acting virus, the course and symptoms of the disease can vary significantly. Peracute, acute, subacute and chronic forms of the disease can be distinguished. So far a few genes were shown to have an impact on the virulence of the virus, including the members of two multigene families (MGF 360 and MGF 505), and the genes DP71L, DP96R and DB69R (UK). Vaccine developments based on classical attenuation and virus inactivation methods failed to produce safe and effective vaccines against ASFV. Based on the available data, it seems that the development of live attenuated vaccines by targeted mutagenesis can bring a breakthrough in vaccine development, however, there are still a lot of problems to be solved. Vaccine research is hampered by the lack of established continuous cell lines in which ASFV can be propagated in high titer without genetic changes. A great variety of immunological and DNA based tests can be applied to diagnose ASFV, however, the use of PCR and immunoperoxidase staining are the most reliable methods used in practice. Since currently there is no available vaccine, the most effective defensive measures against the virus are the implementation of rigorous biosafety and biosecurity standards on the pig farms to prevent viral infection of the livestock.",
author = "F. Olasz and Istv{\`a}n M{\'e}sziros and Vivien Tam{\`a}s and {\^A}dim B{\'e}lint and Matgorzata Bruczynska and Grzegorz Wozniakowski and Zoltin Z{\'e}dori",
year = "2019",
month = "2",
day = "1",
language = "Hungarian",
volume = "141",
pages = "101--115",
journal = "Magyar Allatorvosok Lapja",
issn = "0025-004X",
publisher = "Magyar Mezogazdasag Ltd",
number = "2",

}

TY - JOUR

T1 - Az afrikai sertéspestis jârvânytana és a védekezés lehetôségei

AU - Olasz, F.

AU - Mésziros, Istvàn

AU - Tamàs, Vivien

AU - Bélint, Âdim

AU - Bruczynska, Matgorzata

AU - Wozniakowski, Grzegorz

AU - Zédori, Zoltin

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The first African swine fever (ASF) cases outside Africa were diagnosed in Portugal in 1957. Since 2017 the African swine fever virus (ASFV) has been continuously spreading in Eastern Europe, then it arrived to Asia, and by now it became the biggest economic and animal health threat to the swine industry of the world. In Europe both the wild boar and domestic pig populations are affected by the disease. ASFV is very resistant against environmental and physical effects and it may remain infectious in carcasses for months. This resistance largely contributes to the fact that ASFV infection can be sustained for a prolonged time even in low density wild boar populations. Depending on the infectious route, the virulence of the strain and the quantity of the acting virus, the course and symptoms of the disease can vary significantly. Peracute, acute, subacute and chronic forms of the disease can be distinguished. So far a few genes were shown to have an impact on the virulence of the virus, including the members of two multigene families (MGF 360 and MGF 505), and the genes DP71L, DP96R and DB69R (UK). Vaccine developments based on classical attenuation and virus inactivation methods failed to produce safe and effective vaccines against ASFV. Based on the available data, it seems that the development of live attenuated vaccines by targeted mutagenesis can bring a breakthrough in vaccine development, however, there are still a lot of problems to be solved. Vaccine research is hampered by the lack of established continuous cell lines in which ASFV can be propagated in high titer without genetic changes. A great variety of immunological and DNA based tests can be applied to diagnose ASFV, however, the use of PCR and immunoperoxidase staining are the most reliable methods used in practice. Since currently there is no available vaccine, the most effective defensive measures against the virus are the implementation of rigorous biosafety and biosecurity standards on the pig farms to prevent viral infection of the livestock.

AB - The first African swine fever (ASF) cases outside Africa were diagnosed in Portugal in 1957. Since 2017 the African swine fever virus (ASFV) has been continuously spreading in Eastern Europe, then it arrived to Asia, and by now it became the biggest economic and animal health threat to the swine industry of the world. In Europe both the wild boar and domestic pig populations are affected by the disease. ASFV is very resistant against environmental and physical effects and it may remain infectious in carcasses for months. This resistance largely contributes to the fact that ASFV infection can be sustained for a prolonged time even in low density wild boar populations. Depending on the infectious route, the virulence of the strain and the quantity of the acting virus, the course and symptoms of the disease can vary significantly. Peracute, acute, subacute and chronic forms of the disease can be distinguished. So far a few genes were shown to have an impact on the virulence of the virus, including the members of two multigene families (MGF 360 and MGF 505), and the genes DP71L, DP96R and DB69R (UK). Vaccine developments based on classical attenuation and virus inactivation methods failed to produce safe and effective vaccines against ASFV. Based on the available data, it seems that the development of live attenuated vaccines by targeted mutagenesis can bring a breakthrough in vaccine development, however, there are still a lot of problems to be solved. Vaccine research is hampered by the lack of established continuous cell lines in which ASFV can be propagated in high titer without genetic changes. A great variety of immunological and DNA based tests can be applied to diagnose ASFV, however, the use of PCR and immunoperoxidase staining are the most reliable methods used in practice. Since currently there is no available vaccine, the most effective defensive measures against the virus are the implementation of rigorous biosafety and biosecurity standards on the pig farms to prevent viral infection of the livestock.

UR - http://www.scopus.com/inward/record.url?scp=85062208159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062208159&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85062208159

VL - 141

SP - 101

EP - 115

JO - Magyar Allatorvosok Lapja

JF - Magyar Allatorvosok Lapja

SN - 0025-004X

IS - 2

ER -